Irinotecan in Treating Patients With Recurrent Malignant Glioma

NCT00003301 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: irinotecan hydrochloride

Sponsor

New Approaches to Brain Tumor Therapy Consortium

Collaborators

[object Object]